Signalife, Inc.
(“Company”), (Amex: SGN) announced that it has initiated its cardiovascular
wellness and athletic program. The first engagement will be the most
demanding i.e. testing and utilization with worldwide track and field
athletes as well as nationwide fitness facilities. Through this program the
parties intend to explore protocols for the utilization of Signalife’s
revolutionary product. As is generally acknowledged, ECG devices are rarely
capable of detecting a clinical quality ECG signal in an ambulatory
environment. The selection of Signalife’s flagship Fidelity 100 heart
monitor by Olympic class athletes and internationally-known fitness
facilities, will attempt to utilize the devices during exercise training
environments such as track and field, professional football, tennis and
other sports. Healthcare professionals will be able to gauge numerous
indicators relating to health and athletic performance. One partnership
with the utilization of Signalife’s technology is with Maurice Green, the
current American and Olympic 100 meter champion. Others include, renown
track and field stars such as Leonard Scott (world indoor sprint champion),
Dominque Arnold (American hurdling record holder), and Larry Wade.

Additionally, retired athletes from all sports are in support of the
utilization of the Fidelity 100(TM) for their health and conditioning
needs. For example, Hall of Fame professional running backs Marcus Allen
and Jim Brown, as well as superstars Tim Brown, Marshall Faulk and Willie
Gault, will utilize the Fidelity 100(TM) with their physicians to gauge
their cardiovascular condition. To quote Mr. Gault (formerly voted the
greatest athlete in the world) “It is never too late, or too early, to
learn the actual condition of the most important muscle in the body and to
do something about it.”

Furthermore, Signalife has already entered into understandings with
best of class fitness facilities. The most stress known in the world to
date may be the “under 10-second” 100 meter dash in which the heart muscle
of the athlete literally moves inside the heart’s chest cavity. The
Signalife Fidelity 100(TM) performs flawlessly in that environment. But the
Signalife Fidelity 100(TM) is even more important for the client population
in general, as conditioning and disease states is a matter of degree
spanning a $400 billion cardiovascular industry.

Signalife anticipates numerous expansions in the wellness and
performance arena over the upcoming 120 days, both nationally and
internationally. During this time, look for events at fitness clubs near
you when these athletes will conduct physician prescribed and supervised
demonstrations of the revolutionary Fidelity 100 (TM).

Signalife’s cardiovascular wellness and athletic program has become
increasingly important in light of several recent studies that have
measured the injury to the general population — and the increase in the
cost of health care in general — from unrecognized cardiovascular
abnormalities. By providing clientele, in the exercise and fitness setting,
with the only ambulatory, clinical quality, ECG monitoring device,
Signalife hopes to identify and stratify risks earlier for the benefit of
all those prescribed the device by their physicians.

In the July 27, 2006 addition of Health Day News, the authors stated:

“Heart attacks often go unrecognized, although experts disagree
on just how often. One recent study suggested that 43 percent of
attacks — more than four in 10 — may go undetected when they
occur, and more often in women than men. While other experts say that
estimate is too high, they concede that unrecognized attacks are a
problem…

The researchers gave the men and women a baseline ECG screening
during the years 1990 to 1993, and then repeated the ECGs during
either 1994 to 1995, or 1997 to 2000. The imaging tests revealed
that over 4 out of 10 heart attacks went unrecognized — including
one-third of attacks in men and more than one-half in women, the
study said.

The researchers think the results could apply to any developed
country.”

Under the pact, Signalife has established a series of pilot programs
for athletes — from professionals to “weekend warriors.” The
cardiovascular issues faced by the entire population are paralleled to the
professionals. Indeed, current 100-meter record holder Maurice Greene –
American Record Holder in the 100 Meter dash, Olympic Gold Medalist and
National and International Track and Field Superstar — commented: “People
are under the incorrect impression that professional athletes are not as
sensitive to what is happening in their body than are the general
population. The truth may be just the opposite. We have to be very in tune
with our bodies, because the stress created by national and international
competition is unequalled in terms of the potential short and long term
impact on the athlete’s heart. With the Signalife Fidelity 100(TM) device,
we now for the first time have an easy-to-use (size of a PDA) measuring
stick that provides clear data and trusted results that are useful from
everything to the athletes’ health as well as the data he or she needs to
make intelligent decisions about their performance, their health and their
life. To then be able to have benefits to mankind — with Signalife using
the data to stratify risks across populations and demographics, from the
track to the gym to the jogging trail — is very rewarding for me as a role
model and caring member of society. Looking for all the information I can
get to live a competitive career and life, it was an easy choice for to
begin using the Signalife technologies.”

Mr. Greene continued: “This is not about paid endorsements, and my
relationship with Signalife is not one of them. This is about my health and
the health of the population. If I can assist in helping myself as well as
the general population, there is no way I am going to walk away from the
opportunity. I am extremely proud to be working with a device already
demonstrated to generate a perfect clinical quality ECG signal during the
harsh environment associated with internationally competitive 100-meter
races. To me, the benefits to the population are endless. This is among the
most exciting endeavors I have been involved with both during my career and
prospectively thereafter.”

Of course, third party physician practice groups shall purchase and
utilize the Signalife heart monitoring products in a manner calculated to
achieve the goal of promoting the objectives of its clientele. While the
athletes and organizations are under no obligation to continue any program
beyond one year, it is anticipated that all pacts will be made permanent in
the event the initial testing produce the expected results. Signalife hopes
to be a staple in all endeavors of athletic competition.

Dr. Lowell Harmison — former Principal Deputy of the United States
Department of Health and Human Services, developer of the world’s first
fully implantable artificial heart and member of Signalife’s Board of
Directors — commented on the pact: “It is well established that
cardiovascular problems and athletic performance — as with all diseases
and athletic states — can be better predicted through knowledge. In the
case of a normal person, the key is early detection and early intervention.
As a corollary, health and wellness is obviously maximized by knowing — in
detail and in advance — of any signal-related changes in the person’s ECG
evaluation. The ECG is the gold standard, but no ECG other than ours can
produce a clinical quality signal while following a patient in 9 seconds as
he runs the 100 meters. We are excited to be working alongside
internationally-respected and record- holding athletes as well as national
gyms.”

“It is important to applaud the adoption of Signalife technologies and
to recognize the opportunity we have been given,” states Pamela Bunes,
Signalife’s CEO. “According to statistics provided by the International
Health, Racquet, & Sports Club Association, there are more than 26,000
health and fitness clubs in the US with more than 43 million members.
Health club members focus on their future wellness by adopting a fitness
regimen that can now include ECG evaluations that reflect the improvement
to one’s cardiovascular health after the adoption of an appropriate fitness
regimen. A number of states recently required that gyms keep Automatic
external Defibrillators (AEDs) onsite to address the growing incidence of
sudden cardiac arrest at sports facilities…

Leading up to the wellness and athletic program, Signalife has not only
engaged in extensive and well-known medical testing of its flagship
Fidelity 100(TM) heart monitor, but Signalife has also tested the device in
exercise settings. Indeed, Signalife’s FDA-cleared Fidelity 100 (TM)
produced a clinical quality ECG during strenuous exercise known only to
world class track and field athletes as well as professional race-car
drivers. In these exact settings, the ECG signal was as clear as if the
patient was resting in a physician’s office. Signalife’s research to date
indicates that these ambulatory settings are where cardiovascular
abnormalities are most likely to be detected at the earliest stage and
where performance can best be measured.

About Signalife, Inc.

Signalife, Inc. engages in the research, development, and marketing of
signal-monitoring devices for detecting diseases. It primarily offers
patient modules that are used as part of a heart monitor system to acquire,
amplify, and process physiological signals associated with a patient’s
cardiovascular system. Signalife is based in Greenville, South Carolina.
For more information visit signalife.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are
“forward- looking” statements. Forward-looking statements involve known and
unknown risks, which may cause Signalife’s actual results in the future to
differ materially from expected results. Factors which could cause or
contribute to such differences include, but are not limited to, failure to
complete the development and introduction of heart monitoring and other
biomedical devices incorporating Signalife’s technology, failure to obtain
federal or state regulatory approvals governing heart monitoring and other
biomedical devices incorporating Signalife’s technology, inability to
obtain physician, patient, client or insurance acceptance of for heart
monitoring and other biomedical incorporating Signalife’s technology, and
the unavailability of financing to complete management’s plans and
objectives, including the development of heart monitoring and other
biomedical incorporating Signalife’s technology. Additional risks are found
in clientele acceptance of Signalife’s product-set. These risks are
qualified in their entirety by cautionary language and risk factors set
forth and to be further described in Signalife’s filings with the
Securities and Exchange Commission, but are significant and should be
carefully evaluated by any and all investors.

Signalife, Inc.
signalife